Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188811 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2CA14CA12KMT2ACA7 | |
| SCHEMBL28741307 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2CA14CA12KMT2ATP53 | |
| SCHEMBL5701177 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2CA14CA12KMT2ATP53 | |
| SCHEMBL5328444 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2CA14CA12KMT2ATP53 | |
| SCHEMBL5328441 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2CA14CA12KMT2ATP53 | |
| SCHEMBL856080 | 0.79 | SMN1; SMN2 (0.61) | SMN1; SMN2CA14CA12KMT2ACA7 | |
| SCHEMBL6895304 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2CA14CA12KMT2AECE1 | |
| SCHEMBL20603118 | 0.77 | TSHR (0.42) | SMN1; SMN2CA14CA12TP53SLC7A5 | |
| SCHEMBL6895301 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2CA14CA12KMT2AECE1 | |
| SCHEMBL593998 | 0.76 | TP53 (0.50) | SMN1; SMN2TP53SLC7A5ECE1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624028-B2 | 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250170104-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR Lasß | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2025-05-29 | — | — | US | disclosed |
| EP-4486452-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LASSS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2025-01-08 | — | — | EP | disclosed |
| WO-2023166039-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR Lasß | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166039-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR Lasß | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-09-07 | — | — | WO | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| CN-115715292-A | 1H-pyrazolo [4,3-g ] isoquinoline and 1H-pyrazolo [4,3-g ] quinoline derivatives as alpha-1-antitrypsin modulators for the treatment of alpha-1-antitrypsin deficiency (AATD) | 弗特克斯药品有限公司 | 2023-02-24 | — | — | CN | disclosed |
| EP-4126863-A1 | 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | Vertex Pharmaceuticals Incorporated (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021203025-A1 | 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| CN-102822175-A | 5, 5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS INC (US) | 2012-12-12 | — | — | CN | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | SMN1; SMN2 1200/4885CA14 793/4885CA12 613/4885 |
| US-20250170104-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR Lasß | LTA, SERPINB1, LAS1L | SMN1; SMN2 4878/4885CA14 4397/4885CA12 4284/4885 |
| US-12624028-B2 | 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | SERPINA2, SERPINC1, SERPINH1 | SMN1; SMN2 2089/4885CA14 4591/4885CA12 4109/4885 |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINE1, SERPINA3 | SMN1; SMN2 3099/4885CA14 4805/4885CA12 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.